NTX 470
Alternative Names: NTX-0470; NTX-470Latest Information Update: 21 May 2024
Price :
$50 *
At a glance
- Originator Nutcracker Therapeutics
- Class Antineoplastics; RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Prostate cancer
- Research Urogenital cancer
Most Recent Events
- 15 May 2024 Preclinical trials in Prostate cancer in USA (Parenteral) prior to May 2024
- 15 May 2024 Pharmacodynamics data from preclinical studies in Prostate cancer were released by Nutcracker Therapeutics, prior to May 2024
- 26 Sep 2022 NTX 0470 is available for licensing as of 26 Sep 2022. https://www.nutcrackerx.com/partnering/